(Q38102475)

28 August 2017

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine (English)

1 reference

28 August 2017

1 reference

meningococcal disease

1 reference

4

Gunnstein Norheim

1 reference

28 August 2017

2

Andrew J Pollard

1 reference

28 August 2017

Ouli Xie

1

1 reference

PubMed ID

23623866

28 August 2017

Judith E Mueller

series ordinal

3

1 reference

PubMed ID

23623866

28 August 2017

language of work or name

English

0 references

publication date

24 April 2013

1 reference

28 August 2017

1 reference

28 August 2017

31

1 reference

28 August 2017

27

1 reference

28 August 2017

2852-2861

1 reference

Burden of meningitis and other severe bacterial infections of children in africa: implications for prevention

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Epidemic meningitis, meningococcaemia, and Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Mortality from meningococcal disease during an epidemic in The Gambia, West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Where is the meningitis belt? Defining an area at risk of epidemic meningitis in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal carriage in the African meningitis belt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal carriage by age: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Impact of the serogroup A meningococcal conjugate vaccine, MenAfriVac, on carriage and herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Study of a localized meningococcal meningitis epidemic in Burkina Faso: incidence, carriage, and immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Environmental risk and meningitis epidemics in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal Meningitis: Unprecedented Incidence of Serogroup X--Related Cases in 2006 in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

High sensitivity and specificity of the Pastorex® latex agglutination test for Neisseria meningitidis serogroup A during a clinical trial in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Biological diagnosis of meningococcal meningitis in the African meningitis belt: current epidemic strategy and new perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

PCR-based assay for detection of Neisseria meningitidis capsular serogroups 29E, X, and Z

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

The rise and fall of epidemic Neisseria meningitidis serogroup W135 meningitis in Burkina Faso, 2002-2005.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningitis dipstick rapid test: evaluating diagnostic performance during an urban Neisseria meningitidis serogroup A outbreak, Burkina Faso, 2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Field evaluation of two rapid diagnostic tests for Neisseria meningitidis serogroup A during the 2006 outbreak in Niger

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal carriage and disease--population biology and evolution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Fit genotypes and escape variants of subgroup III Neisseria meningitidis during three pandemics of epidemic meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Clonal waves of Neisseria colonisation and disease in the African meningitis belt: eight- year longitudinal study in northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Manson Lecture. Meningococcal meningitis in Africa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Letter: Recognition of diphtheria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Evaluation of the meningitis epidemics risk model in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Serological typing of meningococci by means of micro-precipitation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Genetic basis for biosynthesis of the (alpha 1-->4)-linked N-acetyl-D-glucosamine 1-phosphate capsule of Neisseria meningitidis serogroup X.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Bacterial meningitis in Burkina Faso: surveillance using field-based polymerase chain reaction testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal factor H binding proteins in epidemic strains from Africa: implications for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal disease in South Africa, 1999-2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Epidemiological patterns of meningococcal meningitis in Niger in 2003 and 2004: under the threat of N. meningitidis serogroup W135.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Outbreaks of serogroup X meningococcal meningitis in Niger 1995-2000

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Serogroup X in meningococcal disease, Western Kenya

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

No evidence for capsule replacement following mass immunisation with meningococcal serogroup C conjugate vaccines in England and Wales

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Workshop on vaccine pressure and Neisseria meningitidis, Annecy, France, 9-11 March 2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal disease in South Australia: incidence and serogroup distribution 1971-1980

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Genotypic analysis of serogroups other than A, B or C of Neisseria meningitidis in China

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

An expanded age range for meningococcal meningitis: molecular diagnostic evidence from population-based surveillance in Asia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal infections in the German Democratic Republic 1971-1984.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Neisseria meningitidis serogroup X sequence type 2888, Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Clonal groupings in serogroup X Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Infections by Neisseria meningitidis serogroup X in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Complement Deficiency Predisposes for Meningitis Due to Nongroupable Meningococci and Neisseria-Related Bacteria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Neisseria meningitidis serogroup X sequence type 767 in Turkey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Diagnosis of meningococcal meningitis in Brazil by use of PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Molecular characteristics and epidemiology of meningococcal carriage, Burkina Faso, 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Predictors of immunity after a major serogroup W-135 meningococcal disease epidemic, Burkina Faso, 2002.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Baseline meningococcal carriage in Burkina Faso before the introduction of a meningococcal serogroup A conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Neisseria meningitidis: an overview of the carriage state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

An improved procedure for the isolation of meningococcal, polysaccharide antigens, and the structural determination of the antigen from serogroup X

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Quantitative proton nuclear magnetic resonance evaluation and total assignment of the capsular polysaccharide Neisseria meningitidis serogroup X.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Relative stability of meningococcal serogroup A and X polysaccharides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Synthesis and biological evaluation of phosphono analogues of capsular polysaccharide fragments from Neisseria meningitidis A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

O-Acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

The polysialic acid-specific O-acetyltransferase OatC from Neisseria meningitidis serogroup C evolved apart from other bacterial sialate O-acetyltransferases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Human immunity to the meningococcus. II. Development of natural immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Cross-Antigenicity and Immunogenicity between Capsular Polysaccharides of Group C Neisseria meningitidis and of Escherichia coli K92

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Dynamics of carriage of Neisseria meningitidis in a group of military recruits: subtype stability and specificity of the immune response following colonization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Carriage of Neisseria meningitidis and Neisseria lactamica in Infants and Children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Natural phosphoglycans containing glycosyl phosphate units: structural diversity and chemical synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

A polymer of N-acetylglucosamine 1-phosphate in the wall of Staphylococcus lactis 2102

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Synthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Thermostable formulations of a hepatitis B vaccine and a meningitis A polysaccharide conjugate vaccine produced by a spray drying method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Updated postlicensure surveillance of the meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlates of protection, and modeling predictions of the duration of herd immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

The impact of conjugate vaccine on carriage of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

The fundamental link between pneumococcal carriage and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Serogroup B meningococcal vaccines-an unfinished story

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Phase I study of a Neisseria meningitidis liposomal vaccine containing purified outer membrane proteins and detoxified lipooligosaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Analysis of the bactericidal response to an experimental Neisseria meningitidis vesicle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Safety review: two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Emergency vaccination against epidemic meningitis in Ghana: Implications for the control of meningococcal disease in West Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Antibiotic susceptibility and characteristics of Neisseria meningitidis isolates from the African meningitis belt, 2000 to 2006: phenotypic and genotypic perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

Bacillus pumilus polysaccharide cross-reactive with meningococcal group A polysaccharide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.036

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.04.036

1 reference

28 August 2017

1 reference

PubMed ID

23623866